Shire Expands Broad Monoclonal Antibody Research Platform, Enters License Agreement for Novimmune Bi-specific Antibody
July 18 2017 - 6:00AM
Shire Expands Broad Monoclonal
Antibody Research Platform, Enters License Agreement for Novimmune
Bi-specific Antibody
Lexington, MA - July 18, 2017
- Shire plc (LSE: SHP, NASDAQ: SHPG), the biotech leader in Rare
Diseases; and Novimmune S.A., a privately-held Swiss
biopharmaceutical company focused on the discovery and development
of innovative, antibody-based medicines today announced they have
entered into an agreement granting Shire exclusive worldwide rights
to develop and commercialize an innovative, bi-specific antibody in
pre-clinical development for the treatment of hemophilia A and
hemophilia A patients with inhibitors. Shire is leading the
development of the program to optimize and evaluate a fully-human,
bi-specific IgG antibody targeting FIXa and FX, designed to imitate
the body's natural mechanism of Factor VIII-driven coagulation. The
company's ultimate aim is to deliver a treatment that improves upon
the strong and long-term record of efficacy and safety that has
been set by the Factor class.
"This novel program builds on our extensive
monoclonal antibody (MAb) capabilities, as well as on our in-depth
scientific expertise in hematology," said Fritz Scheiflinger, Head
Global Research, Shire. "While further development and clinical
trials are needed to fully evaluate this antibody, we are
encouraged by the potential of the data that we have seen in early
discovery and the promise it may hold for hemophilia A patients and
patients with inhibitors."
Shire has been steadily building its MAb research
capability, which now includes MAb programs in hereditary
angioedema (HAE), diabetic macular edema, antibody-mediated
autoimmune disease, and anti-thrombotic therapy-all signatures of
Shire's new Rare Diseases Innovation Center coming to Cambridge,
MA.
"Novimmune is building on a collaboration
initiated in 2015 with Shire to generate and evaluate Factor
VIII-mimetic, bi-specific antibodies," said Ed Holdener, Chairman
and CEO of Novimmune. "We are delighted that our research efforts
have produced several promising and potentially highly
differentiated leads for improving coagulation in hemophilia
A."
Novimmune has been developing a platform for
making fully human, bi-specific antibodies and has several in-house
programs targeting tumor associated antigens and the immune system
check point protein CD47.
The specific terms of this deal were not
disclosed.
For further information please
contact:
Media Relations |
|
|
Elizabeth Kalina |
ekalina@shire.com |
+1 781 482 2713 |
Gwen Fisher |
gfisher@shire.com |
+1 781 482 9649 |
Investor Relations |
|
|
Ian Karp |
ikarp@shire.com |
+1 781 482 9018 |
Robert Coates |
rcoates@shire.com |
+44 1256 894874 |
NOTES TO EDITORS
About Shire
Shire is the leading global biotechnology company
focused on serving people with rare diseases and other highly
specialized conditions. We strive to develop best-in-class
products, many of which are available in more than 100 countries,
across core therapeutic areas including Hematology, Immunology,
Neuroscience, Ophthalmics, Lysosomal Storage Disorders,
Gastrointestinal / Internal Medicine / Endocrine and Hereditary
Angioedema; and a growing franchise in Oncology.
Our employees come to work every day with a shared
mission: to develop and deliver breakthrough therapies for the
hundreds of millions of people in the world affected by rare
diseases and other high-need conditions, and who lack effective
therapies to live their lives to the fullest.
www.shire.com
About
Novimmune
Novimmune SA is a privately held, Swiss
biopharmaceutical company focused on the discovery and development
of antibody-based drugs for the targeted treatment of inflammatory
diseases, immune-related disorders, and cancer. The company is
headquartered in Geneva and runs a Clinical and Commercial
Development Center in Basel. The company currently employs 130
people. More information is available on the company website at
www.novimmune.com.
For further information please
contact:
Adrian
Mills
|
amills@novimmune.com |
+41 (0)
61 201 13 27
|
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Shire plc via Globenewswire
Shire (LSE:SHP)
Historical Stock Chart
From Apr 2024 to May 2024
Shire (LSE:SHP)
Historical Stock Chart
From May 2023 to May 2024